To account for a product financing arrangement, record the cash you receive as a financing liability rather than revenue, keep the transferred inventory on your balance sheet, accrue interest expense across the holding period, and extinguish the liability when you repurchase. Under ASC 470-40, this treatment is mandatory whenever the repurchase price covers the counterparty’s original transfer amount plus its carrying and financing costs, because the economic reality is a collateralized loan.1Financial Accounting Standards Board. Summary of Statement No. 49 Sale treatment is almost never appropriate for these transactions, and getting the classification wrong overstates revenue, understates debt, and inflates operating cash flow in one stroke.
The Test That Forces Financing Treatment
ASC 470-40 applies whenever two conditions are met. First, the sponsor has an obligation, or an option it is expected to exercise, to repurchase the product, a substantially identical product, or processed goods made from the original product. A binding forward commitment qualifies; so does a call option priced so exercise is virtually certain. Second, the repurchase price shields the other party from ownership risk, typically because the formula equals the original transfer price plus storage, insurance, and a financing return.1Financial Accounting Standards Board. Summary of Statement No. 49 When both are present, financing treatment is required with no discretion, regardless of what the legal documents call the transaction.
ASC 606 reaches the same conclusion by a different route. Under ASC 606-10-55-70, a seller that retains a forward repurchase obligation or a call option has not transferred control, so no revenue is recognized. If the repurchase price equals or exceeds the original selling price, ASC 606 classifies the arrangement as a financing: the seller continues to recognize the asset, records a financial liability for the cash received, and treats the difference between the cash received and the repurchase price as interest expense over the term. Put options work the same way when the buyer has a significant economic incentive to exercise, meaning the repurchase price exceeds both the original selling price and the expected market value at the repurchase date.2Financial Accounting Standards Board. Revenue from Contracts with Customers (Topic 606) – Section A
One wrinkle worth noting: if a call option lapses unexercised, the sponsor derecognizes the liability and recognizes revenue at that point.2Financial Accounting Standards Board. Revenue from Contracts with Customers (Topic 606) – Section A
Journal Entries at Each Stage
At Inception
The cash the sponsor receives from the counterparty is recorded as a financing obligation. The inventory stays on the sponsor’s books at its existing carrying value; it can be reclassified to a line such as “inventory pledged under financing arrangement,” but it is not derecognized. No revenue is recognized and no cost of goods sold is recorded. On the other side, the counterparty carries a receivable from the sponsor, not inventory.
A worked example makes the mechanics concrete. A sponsor transfers $1,000,000 of inventory and receives $980,000 in cash, the small difference reflecting an upfront discount. The entry is a debit to cash of $980,000 and a credit to financing obligation of $980,000. The inventory account is unchanged.
During the Holding Period
Interest expense accrues over time, representing the financing return owed to the counterparty. Storage, insurance, and any other holding costs the sponsor is obligated to reimburse are expensed as incurred. The liability balance grows by accrued but unpaid interest. Because the sponsor still bears the economic risk of the inventory, the goods remain subject to normal lower-of-cost-or-net-realizable-value testing.
At Repurchase
When the sponsor repurchases the product, it pays the agreed price, which covers principal, accrued financing costs, and any holding-cost reimbursement. The financing obligation is debited and extinguished, the final interest expense is recorded, and cash is credited. The inventory is already on the books and is now available for sale through normal channels.
Cash Flow Statement Treatment
The cash flow statement has to reflect the financing character of the transaction. The initial cash received is a financing inflow, not an operating inflow. At repurchase, the principal portion of the payment is a financing outflow, and the interest portion is generally an operating outflow, consistent with how interest on other debt is presented.
Classifying the initial cash as an operating receipt, and the repurchase as an inventory purchase, is one of the more common errors in this area. It inflates operating cash flow, which is a figure lenders and analysts watch closely, and it draws regulatory attention.
Footnote Disclosures Required
Financial statement footnotes have to give readers enough information to understand the arrangement and its financial impact. At a minimum, cover:
- Nature and purpose of the arrangement, including the relationship between the sponsor and the counterparty and whether the counterparty is a related entity or a special purpose entity created for the transaction.
- Repurchase terms: the date or window, the price formula, and the effective interest rate or financing return embedded in the deal.
- Carrying value of the inventory pledged or held under the arrangement as of the balance sheet date.
- The total financing liability outstanding, split between current and non-current portions.
- An explicit statement that the transaction is accounted for as a financing rather than a sale.
SEC registrants have an additional layer under Regulation S-K. If a product financing arrangement could materially affect liquidity, capital resources, or results of operations, it needs to be discussed in Management’s Discussion and Analysis.
When a Special Purpose Entity Is Involved
If the counterparty is a special purpose entity created at the sponsor’s direction, the sponsor needs to evaluate consolidation under the variable interest entity rules in ASC 810. When the sponsor absorbs the majority of the entity’s expected losses or receives the majority of its expected residual returns, it is the primary beneficiary and must consolidate.
Consolidation is often the answer here, because the sponsor controls the entity’s activities and is exposed to the full economic risk through its repurchase commitment. On consolidation, the intercompany transaction is eliminated entirely, so the consolidated financials look the same as if the sponsor had applied financing treatment to a standalone arrangement: the inventory sits on the balance sheet, the external borrowing shows as debt, and no intercompany revenue appears.
When Sale Treatment Might Actually Apply
Sale treatment is rare and worth being skeptical of. For a sale to be recognized, the counterparty must take on real ownership risk, including exposure to market price declines, obsolescence, and demand uncertainty, and must not be guaranteed a return by the sponsor. If those conditions genuinely hold, the sponsor recognizes revenue on transfer, removes the inventory, and records cost of goods sold; any later repurchase is treated as a new inventory purchase at the then-current price.
In practice, an arrangement that truly transfers all risks and rewards to the counterparty is usually not a product financing arrangement at all. It is an ordinary sale that happens to be followed by an unrelated repurchase.
Why the Classification Is Worth Getting Right
Revenue recognition has consistently been one of the SEC’s top enforcement priorities, and the agency has increased its focus on holding individual executives accountable alongside the companies involved. Misclassifying a product financing arrangement as a sale is exactly the pattern that draws attention: it overstates revenue, understates liabilities, and inflates operating cash flow at the same time. That combination is hard to characterize as an honest mistake, and companies that have restated in this area have typically faced audit committee investigations, multiple restated periods, and lasting credibility damage.
When the counterparty has a guaranteed return and the sponsor keeps the risk, the accounting answer is financing treatment. Reaching for a technical argument to book revenue is not worth the restatement exposure.